Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib

NCT02185560 · clinicaltrials.gov ↗

ACTIVE_NOT_RECRUITING

Status

453

Enrollment

INDUSTRY

Sponsor class

Conditions

Thyroid Carcinoma

Interventions

DRUG: Sorafenib (Nexavar, BAY43-9006)

Sponsor

Bayer